全文获取类型
收费全文 | 4201篇 |
免费 | 275篇 |
国内免费 | 14篇 |
专业分类
耳鼻咽喉 | 40篇 |
儿科学 | 84篇 |
妇产科学 | 74篇 |
基础医学 | 720篇 |
口腔科学 | 53篇 |
临床医学 | 425篇 |
内科学 | 833篇 |
皮肤病学 | 142篇 |
神经病学 | 428篇 |
特种医学 | 184篇 |
外科学 | 401篇 |
综合类 | 27篇 |
一般理论 | 1篇 |
预防医学 | 383篇 |
眼科学 | 78篇 |
药学 | 210篇 |
中国医学 | 5篇 |
肿瘤学 | 402篇 |
出版年
2023年 | 27篇 |
2022年 | 60篇 |
2021年 | 101篇 |
2020年 | 77篇 |
2019年 | 76篇 |
2018年 | 110篇 |
2017年 | 82篇 |
2016年 | 112篇 |
2015年 | 138篇 |
2014年 | 147篇 |
2013年 | 227篇 |
2012年 | 335篇 |
2011年 | 378篇 |
2010年 | 184篇 |
2009年 | 188篇 |
2008年 | 289篇 |
2007年 | 296篇 |
2006年 | 299篇 |
2005年 | 282篇 |
2004年 | 264篇 |
2003年 | 216篇 |
2002年 | 196篇 |
2001年 | 36篇 |
2000年 | 17篇 |
1999年 | 31篇 |
1998年 | 42篇 |
1997年 | 44篇 |
1996年 | 31篇 |
1995年 | 21篇 |
1994年 | 24篇 |
1993年 | 25篇 |
1992年 | 13篇 |
1991年 | 7篇 |
1990年 | 5篇 |
1989年 | 7篇 |
1988年 | 7篇 |
1987年 | 9篇 |
1986年 | 6篇 |
1985年 | 4篇 |
1984年 | 7篇 |
1983年 | 5篇 |
1982年 | 5篇 |
1980年 | 6篇 |
1979年 | 4篇 |
1978年 | 5篇 |
1977年 | 6篇 |
1964年 | 3篇 |
1939年 | 6篇 |
1936年 | 3篇 |
1923年 | 3篇 |
排序方式: 共有4490条查询结果,搜索用时 15 毫秒
81.
82.
Horstkotte D Lengyel M Mistiaen WP Piper C Völler H;Working Group on Infection Thrombosis Embolism Bleeding of the Society of;Heart Valve Disease 《The Journal of heart valve disease》2005,14(1):1-7
Major reasons for the considerable heterogeneity among published results of heart valve surgery are inconsistency in follow up techniques, reporting systems and classification of adverse events. The present recommendations are intended to harmonize the presentation of clinical material in order to improve comparison of data from different sources for the analysis of pooled data. The quality of an observational study is largely, if not entirely, due to the follow up technique, which may be graded according to six categories: Self-reporting of adverse events/well-being by the patients may be classified 'excellent'; if the information is gathered and re-checked at short-term intervals. Data obtained from in-hospital or outpatient examinations by qualified examiners at least twice a year or other personal contact through qualified examiners may be regarded as 'sufficient', if the results are re-checked by contacting the treating home physician. All other follow up techniques may be regarded as inappropriate. Consequences of complications are entirely dependent on severity and possible sequelae. It is therefore recommended to grade any reported complication according to its severity by utilizing a score system. Embolisms are best categorized by utilizing the performance status scale. Bleeding events may be categorized according to severity as fatal, major (requiring hospital transmission with transfusion, surgery or with permanently increased disability) or minor (not requiring hospital admission, surgery or transfusion). In some cases it will remain unclear whether an event was primarily embolic or hemorrhagic. These complications should be summarized as 'not categorized'. The reporting of morbid events due to thrombosis, embolism and bleeding should go along with information regarding the quality of antithrombotic management. 相似文献
83.
Cornelia Speich Rita Wegmüller Gary M. Brittenham Christophe Zeder Colin I. Cercamondi Daniela Buhl Andrew M. Prentice Michael B. Zimmermann Diego Moretti 《British journal of haematology》2021,192(1):179-189
We report the first measurements of long‐term iron absorption and loss during iron supplementation in African children using a stable isotope of iron (57Fe). After uniform labelling of body iron with 57Fe, iron absorption is proportional to the rate of decrease in the 57Fe tracer concentration, while iron loss is proportional to the rate of decrease in the 57Fe tracer amount. Anaemic Gambian toddlers were given 2 mg 57Fe orally to equilibrate with total body iron over 8–11 months. After assignment to the positive control arm of the HIGH study, 22 toddlers consumed a micronutrient powder containing 12 mg iron for 12 weeks followed by 12 weeks without iron supplementation. Their daily iron absorption increased 3·8‐fold during the iron supplementation period compared to the control period [median (interquartile range, IQR): 1·00 (0·82; 1·28) mg/day vs. 0·26 (0·22; 0·35) mg/day; P = 0·001]. Unexpectedly, during the supplementation period, daily iron loss also increased by 3·4‐fold [0·75 (0·55; 0·87) mg/day vs. 0·22 (0·19; 0·29) mg/day; P = 0·005]. Consequently, most (~72%) of the absorbed iron was lost during supplementation. Long‐term studies of iron absorption and loss are a promising and accurate method for assessing and quantifying long‐term iron balance and may provide a reference method for evaluating iron intervention programs in vulnerable population groups. This study was registered as ISRCTN 0720906. 相似文献
84.
Tae Hwan Kim Soyoung Shin Cornelia B. Landersdorfer Yong Ha Chi Soo Heui Paik Jayhyuk Myung Rajbharan Yadav Stefan Horkovics-Kovats Jürgen B. Bulitta Beom Soo Shin 《The AAPS journal》2015,17(5):1210-1223
Enterohepatic recirculation (EHC) can greatly enhance plasma drug exposures and therapeutic effects. This study aimed to develop a population pharmacokinetic model that can simultaneously characterize the extent and time-course of EHC in three species using fimasartan, a novel angiotensin II receptor blocker, as a model drug. All fimasartan plasma concentration profiles in 32 rats (intravenous doses, 0.3–3 mg/kg; oral doses, 1–10 mg/kg), 34 dogs (intravenous doses, 0.3–1 mg/kg; oral doses, 1–10 mg/kg), and 42 healthy volunteers (single or multiple oral doses, 20–480 mg) were determined via liquid chromatography-tandem mass spectrometry (LC-MS/MS) and simultaneously modeled in S-ADAPT. The proposed model quantitatively characterized EHC in three species after oral and intravenous dosing. The median (range) fraction of drug undergoing recirculation was 76.3% (64.9–88.7%) in rats, 33.3% (24.0–45.9%) in dogs, and 65.6% (56.5–72.0%) in humans. In the presence compared with the absence of EHC, the area under the curve in plasma was predicted to be 4.22-fold (2.85–8.85) as high in rats, 1.50-fold (1.32–1.85) in dogs, and 2.91-fold (2.30–3.57) in humans. The modeled oral bioavailability in rats (median (range), 38.7% (20.0–59.8%)) and dogs (median, 7.13% to 15.4%, depending on the formulation) matched the non-compartmental estimates well. In humans, the predicted oral bioavailability was 25.1% (15.1–43.9%) under fasting and 18.2% (12.2–31.0%) under fed conditions. The allometrically scaled area under the curve predicted from rats was 420 ng ⋅ h/mL for 60 mg fimasartan compared with 424 ± 63 ng ⋅ h/mL observed in humans. The developed population pharmacokinetic model can be utilized to characterize the impact of EHC on plasma drug exposure in animals and humans.
Electronic supplementary material
The online version of this article (doi:10.1208/s12248-015-9764-2) contains supplementary material, which is available to authorized users.KEY WORDS: animal to human scaling, enterohepatic recirculation, fimasartan, population pharmacokinetics, S-ADAPT 相似文献85.
86.
Dina Vojinovic Hieab HH Adams Sven J van der Lee Carla A Ibrahim-Verbaas Rutger Brouwer Mirjam CGN van den Hout Edwin Oole Jeroen van Rooij Andre Uitterlinden Albert Hofman Wilfred FJ van IJcken Annemieke Aartsma-Rus GertJan B van Ommen M Arfan Ikram Cornelia M van Duijn Najaf Amin 《European journal of human genetics : EJHG》2015,23(6):837-843
The aim of our study is to investigate whether single-nucleotide dystrophin gene (DMD) variants associate with variability in cognitive functions in healthy populations. The study included 1240 participants from the Erasmus Rucphen family (ERF) study and 1464 individuals from the Rotterdam Study (RS). The participants whose exomes were sequenced and who were assessed for various cognitive traits were included in the analysis. To determine the association between DMD variants and cognitive ability, linear (mixed) modeling with adjustment for age, sex and education was used. Moreover, Sequence Kernel Association Test (SKAT) was used to test the overall association of the rare genetic variants present in the DMD with cognitive traits. Although no DMD variant surpassed the prespecified significance threshold (P<1 × 10−4), rs147546024:A>G showed strong association (β=1.786, P-value=2.56 × 10−4) with block-design test in the ERF study, while another variant rs1800273:G>A showed suggestive association (β=−0.465, P-value=0.002) with Mini-Mental State Examination test in the RS. Both variants are highly conserved, although rs147546024:A>G is an intronic variant, whereas rs1800273:G>A is a missense variant in the DMD which has a predicted damaging effect on the protein. Further gene-based analysis of DMD revealed suggestive association (P-values=0.087 and 0.074) with general cognitive ability in both cohorts. In conclusion, both single variant and gene-based analyses suggest the existence of variants in the DMD which may affect cognitive functioning in the general populations. 相似文献
87.
Flexible selection of a single treatment incorporating short‐term endpoint information in a phase II/III clinical trial 下载免费PDF全文
Nigel Stallard Cornelia Ursula Kunz Susan Todd Nicholas Parsons Tim Friede 《Statistics in medicine》2015,34(23):3104-3115
Seamless phase II/III clinical trials in which an experimental treatment is selected at an interim analysis have been the focus of much recent research interest. Many of the methods proposed are based on the group sequential approach. This paper considers designs of this type in which the treatment selection can be based on short‐term endpoint information for more patients than have primary endpoint data available. We show that in such a case, the familywise type I error rate may be inflated if previously proposed group sequential methods are used and the treatment selection rule is not specified in advance. A method is proposed to avoid this inflation by considering the treatment selection that maximises the conditional error given the data available at the interim analysis. A simulation study is reported that illustrates the type I error rate inflation and compares the power of the new approach with two other methods: a combination testing approach and a group sequential method that does not use the short‐term endpoint data, both of which also strongly control the type I error rate. The new method is also illustrated through application to a study in Alzheimer's disease. © 2015 The Authors. Statistics in Medicine Published by John Wiley & Sons Ltd. 相似文献
88.
89.
90.